Pharmaceutical Supply Chain Defense and Enhancement Act

The Pharmaceutical Supply Chain Defense and Enhancement Act creates a confidential list of drugs critical to public health and national security, requiring manufacturers to report on supply chain dependencies and develop continuity plans. It authorizes $5 billion to boost domestic manufacturing capacity for these critical drugs and their ingredients through contracts with U.S. companies, prioritizing generic drugs and drugs not currently manufactured in the U.S. Federal agencies must prioritize purchasing domestically manufactured drugs from the critical list, with $1 billion annually allocated for this purpose. The bill also mandates annual transparency reports on supply chain reliance and includes oversight of foreign investment in the U.S. pharmaceutical industry.